Kumar Budur promoted to EVP and Chief Medical & Scientific Officer at Harmony Biosciences

Harmony Biosciences Holdings, Inc.

Appointed EVP & Chief Medical & Scientific Officer effective May 1, 2024.
Annual salary raised from $500,000 to $575,000; target bonus remains 50% of salary.
Receives 75,000 RSUs and 75,000 stock options vesting over four years.
Dr. Budur had been Chief Medical Officer; biography previously disclosed in proxy.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Kumar Budur

Executive Vice President and Chief Medical & Scientific Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2024-05-01
Filed: May 3, 2024, 7:59 PM ET

appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Officer (the “Appointment”), effective on May 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kumar Budur was appointed as Executive Vice President and Chief Medical & Scientific Officer at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Executive Vice President and Chief Medical & Scientific Officer

Exact text from the filing

appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Officer (the “Appointment”), effective on May 1, 2024

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-006594

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.